Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNCs for Cerebral Palsy
NCT02574923Phase 2Completed
- Sponsor
- Vinmec Healthcare System
- Start
- Nov 2015
- Primary completion
- Mar 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in cerebral palsy (CP), sponsored by Vinmec Healthcare System. Primary endpoints: Gross Motor Function Measure-88 Total Score at 6 months and Gross Motor Function Measure-66 Percentile at 6 months. Started Nov 2015; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT02574923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574923.